Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-06-25 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
THIRD ANNOUNCEMENT TO CREDITORS OF THE COMPANY IN RELATION TO GENERAL MANDATE GRANTED TO THE BOARD TO REPURCHASE H SHARES OF THE COMPANY
Capital/Financing Update Classification · 95% confidence The document is an announcement made pursuant to disclosure requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. It informs creditors about the general mandate granted to the board to repurchase H shares and provides instructions for creditors to submit claims. The content focuses on the repurchase mandate and creditor claims rather than financial results or detailed financial data. It is not a full financial report, earnings release, or management discussion. The document is a formal announcement related to share repurchase authorization and creditor notification, which aligns with a Capital/Financing Update. The length is about 4985 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-06-25 English
SECOND ANNOUNCEMENT TO CREDITORS OF THE COMPANY IN RELATION TO GENERAL MANDATE GRANTED TO THE BOARD TO REPURCHASE H SHARES OF THE COMPANY
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to disclosure requirements under the Hong Kong Stock Exchange rules. It concerns a general mandate granted to the board to repurchase H shares and provides instructions to creditors on how to claim creditor's rights. The content is regulatory in nature, related to compliance and creditor notification, without any financial statements or detailed financial data. The document is about a corporate action announcement and creditor notification rather than a financial report or detailed management discussion. It is not a report itself but an announcement related to a corporate mandate and creditor claims. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-06-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED POSITIVE GAVRETO REGISTRATIONAL STUDY DATA FOR FIRST-LINE TREATMENT OF ADVANCED RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER AND PLANS TO SUBMIT A NEW INDIC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding positive clinical study data for their drug GAVRETO and plans to submit a new indication application to the China National Medical Products Administration (NMPA). It discusses clinical trial results, regulatory plans, and drug approvals but does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a call transcript or management discussion. The document is an announcement of clinical and regulatory progress, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical trial results and regulatory submission plans. The document length is over 12,000 characters, so it is not a brief report publication announcement. There is no indication of board changes, voting results, or capital changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-06-24 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 23, 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on June 23, 2021, for CStone Pharmaceuticals. It details the voting outcomes on various resolutions including approval of audited financial statements, re-election of directors, appointment of auditors, and share issuance mandates. The document does not contain the full financial report or detailed financial statements but rather the official voting results from the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 5684 characters, which is sufficient to include detailed voting results but not a full report. Therefore, the correct classification is DVA with high confidence.
2021-06-23 English
ANNOUNCEMENT IN RELATION TO THE RESOLUTIONS PASSED AT THE 2021 FIRST CLASS MEETING OF THE HOLDERS OF A SHARES AND THE RESOLUTIONS PASSED AT THE 2021 FIRST CLASS MEETING OF THE HOLDERS OF H SHARES
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the resolutions passed at the 2021 first class meetings of holders of A shares and H shares of Yanzhou Coal Mining Company Limited. It includes information about the meeting date, venue, attendance, voting results, compliance with laws and regulations, presence of scrutineers and lawyers, and legal opinions confirming the validity of the meetings and voting. The document does not contain financial statements or detailed financial performance data but focuses on the official results of shareholder votes at these class meetings. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length (10,572 characters) is sufficient to be a full announcement rather than a brief notice or a report publication announcement. Therefore, the appropriate classification is DVA with high confidence.
2021-06-18 English
ANNOUNCEMENT IN RELATION TO THE RESOLUTIONS PASSED AT THE 2020 ANNUAL GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the resolutions passed at the 2020 Annual General Meeting (AGM) of Yanzhou Coal Mining Company Limited. It includes information about the date and venue of the AGM, attendance of shareholders and directors, voting results on various resolutions including approval of financial statements, profit distribution, remuneration, and amendments to the Articles of Association. The document explicitly states it is an announcement of the resolutions passed at the AGM, not the full AGM materials or presentations themselves. It also includes dividend declarations as part of the resolutions passed. Given the detailed voting results and the nature of the content, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full Annual Report, nor a Management Report, nor a Proxy Solicitation. It is not a short notice or a report publication announcement but a substantive announcement of AGM voting outcomes.
2021-06-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.